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Abstract
Background—Type 2 diabetes mellitus is associated with dementia risk, however evidence is 
limited for possible associations of diabetes and pre-diabetes with cognitive decline.
Objective—To determine if diabetes in mid-life is associated with 20-year cognitive decline, and 
to characterize long-term cognitive decline across clinical categories of hemoglobin A1c (HbA1c).
Design—Prospective cohort.
Setting—The community-based Atherosclerosis Risk in Communities (ARIC) Study.
Participants—13351 black and white adults aged 48-67 years at baseline (1990-1992).
Measurements—Diabetes was defined by self-report of physician diagnosis or medication use 
or HbA1c≥6.5%. Undiagnosed diabetes, pre-diabetes, and glucose control in persons with 
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diagnosed diabetes were defined using clinical categories of HbA1c. Delayed Word Recall, Digit 
Symbol Substitution, and Word Fluency tests were used to assess cognitive performance, and were 
summarized using a global Z-score.
Results—Diabetes in midlife was associated with significantly greater cognitive decline over 20 
years (adjusted global Z-score difference=-0.15, 95% CI:-0.22,-0.08), representing a 19% greater 
decline than those without diabetes. Cognitive decline was significantly greater among persons 
with pre-diabetes (HbA1c 5.7-6.4%) than those without diabetes and HbA1c<5.7%. Participants 
with poorly controlled diabetes (HbA1c≥7.0%) had a larger decline compared to persons whose 
diabetes was controlled (adjusted global Z-score difference=-0.16,p-value=0.071). Longer 
duration of diabetes was also associated with greater late-life cognitive decline (p-value-for-
trend=<0.001). No significant differences in the rates of declines were seen in whites compared to 
blacks (p-value-for-interaction=0.4357).
Limitations—Single measurement of HbA1c at baseline, only one test to per cognitive domain, 
potential geographic confounding of race comparisons.
Conclusions—These findings suggest that diabetes prevention and glucose control in midlife 
may protect against late-life cognitive decline.
Introduction
The prevalence of diabetes has increased substantially over the past several decades, with a 
current prevalence of approximately 10%, affecting 21 million adults in the U.S.(1). Type 2 
diabetes is an established risk factor for heart disease, stroke, hypertension, blindness, and 
kidney disease(2-4). The association of diabetes with dementia risk is well established(5-7). 
The association of diabetes with cognitive decline, however, is less well characterized. 
Because cognitive decline is a precursor to dementia, strong risk factors for decline can help 
identify persons who may realize the benefits of early intervention. The effects of diabetes 
and early hyperglycemic states assessed in mid-life on long-term cognitive decline are 
relatively uncharacterized(6). Previous studies have been limited by short duration of 
follow-up, lack of rigorous adjustment for potential confounding variables, and most were 
limited to whites and conducted in elderly populations, where associations tend to be 
weaker(8, 9).
Hemoglobin A1c (HbA1c) is a measure of average circulating glucose in the blood over the 
preceding 2 to 3 months. HbA1c is the standard measure used in the clinical management of 
diabetes control and is now recommended for the use for diagnosis of diabetes and 
identification of persons at risk for future diabetes(10). Studies have shown cross-sectional 
associations between HbA1c and cognitive scores in persons with diabetes(11, 12). However 
there is little evidence prospectively linking better glycemic control to slower cognitive 
decline and few studies have examined the association of chronic hyperglycemia below the 
threshold for a diagnosis of diabetes with long-term cognitive impairment(13-15).
Our objective was to examine the association of diabetes assessed in middle-age with 
subsequent 20-year cognitive decline in a community-based population of black and white 
adults. We also examined the associations of hyperglycemia below the threshold for a 
diagnosis of diabetes (i.e. “pre-diabetes”) and glycemic control in the setting of diabetes 
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with 20-year cognitive decline. An inherent challenge to accurately quantifying the long-
term risk factor associations in observational studies is that participants who are ill are less 
likely to return for study visits. In this study, we use methods to account for this attrition, 




The Atherosclerosis Risk in Communities Study (ARIC) is a community-based prospective 
cohort of 15,792 middle aged adults from four U.S. communities: Washington County, 
Maryland; Forsyth County, North Carolina; suburbs of Minneapolis, Minnesota; and 
Jackson, Mississippi. The Jackson field center recruited only blacks and Forsyth recruited 
both blacks and whites. The other two field centers, like Jackson and Forsyth, selected 
participants by probability sampling; however the racial distribution in these locations at that 
time resulted in only a small percentage of non-white participants. Participants were seen at 
four visits approximately three years apart beginning in 1987-1989. A fifth ARIC visit took 
place in 2011-2013. Cognitive function was evaluated at visits 2 (1990-1992), 4 
(1996-1998), and at visit 5 (2011-2013) as part of the ARIC Neurocognitive Study (ARIC-
NCS). Detailed information about ARIC can be found elsewhere(16).
Baseline for the present analysis was visit 2, the first visit where cognitive data were 
collected. Of the 14,348 participants who attended visit 2, we excluded participants who 
were neither white nor black and the small number of blacks in the Minnesota and 
Washington county cohorts (n=91), those who were missing one or more cognitive function 
tests at baseline (n=217), and those missing variables of interest (n=689), giving a final 
sample size of 13,351 participants at baseline (93% of the visit 2 sample). A flow diagram of 
the study population and the pattern of visit attendance is included in the 
Appendix(eFigure1).
Assessment of Cognitive Function
Three cognitive tests were used to assess cognitive function: the Delayed Word Recall Test 
(DWRT)(17), the Digit Symbol Substitution Test (DSST) of the Wechsler Adult Intelligence 
Scale-Revised (WAIS-R)(18), and the Word Fluency Test (WFT)(19). Protocols for the 
neuropsychological tests were standardized, and trained examiners administered the tests in 
a fixed order during one session in a quiet room.
The DWRT is a test of verbal learning and recent memory. Participants were asked to learn 
10 common nouns by using each in a sentence. Two exposures to each word were given. 
After a five-minute filled delay, participants had 60 seconds to recall the words. The score 
for the DWRT is the number of words recalled.
The DSST is a test of executive function and processing speed. In this 90-second test, 
participants were asked to translate numbers to symbols using a key. The score is the count 
of numbers correctly translated to symbols, with a range of possible scores of 0 to 93.
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The WFT is a test of executive function and language. Participants were given 60 seconds 
for each of the letters F, A and S, and were asked to generate as many words as possible 
beginning with each letter, avoiding proper nouns. The WFT score is the total number of 
words generated for each of the letters.
To facilitate comparison across cognitive tests, Z scores standardized to visit 2 were 
calculated for each test by subtracting each participant's test score at each visit from the visit 
2 mean and dividing by the visit 2 standard deviation. A composite global cognitive Z score 
was calculated by averaging the Z scores of the three tests, and was then standardized to 
visit 2 using the global Z mean and global Z standard deviation from visit 2. Thus, a Z score 
of -1 would describe cognitive performance that is 1 standard deviation below the mean 
score at visit 2. Composite global scores derived in this manner have been used in analyses 
of cognitive change in ARIC(20, 21) and elsewhere(22-24).
Assessment of Diabetes
Diabetes was defined based on self-reported physician diagnosis, diabetes medication use, or 
HbA1c ≥ 6.5%.
Measurement of Hemoglobin A1c
HbA1c was measured in stored whole blood samples using high-performance liquid 
chromatography methods standardized to the Diabetes Control and Complications Trial 
assay (Tosoh A1c 2.2 Plus and Tosoh G7 analyzers, Tosoh, Tokyo, Japan)(25). For analyses 
of the association between HbA1c category and cognitive decline, HbA1c was categorized 
using standard clinical cut-points: in persons without a history of diabetes, <5.7%,
5.7-6.4%,≥6.5%; and in persons with a history of diabetes, <7.0% and ≥7.0%(10).
Covariates
All covariates used in the regression models were assessed during visit 2 except education, 
race, and sex, which were assessed during visit 1. The following covariates were evaluated 
as confounders: age, age-squared, sex, race-field center (Minnesota whites; Maryland 
whites; North Carolina whites; North Carolina blacks; Mississippi blacks), education (<high 
school; high school, high school equivalent, or vocational school; college, graduate, or 
professional school), cigarette smoking (current; former; never), alcohol consumption 
(current; former; never), body mass index (kg/m2), hypertension (yes; no – “yes” defined as 
blood pressure-lowering medication use, systolic blood pressure greater than 140 mmHg, or 
diastolic blood pressure greater than 90 mmHg), history of coronary heart disease(yes;no – 
persons who were unsure of their history of heart disease were classified as “no”), history of 
stroke(yes;no), and apolipoprotein E ε4 genotype(0;1;2 alleles). We also included 
interaction terms between these variables and time to allow for different rates of decline by 
these covariates. In sensitivity analyses we treated the following variables as time-varying, 
updating values at each study visit: cigarette smoking, alcohol consumption, body mass 
index, hypertension, history of coronary heart disease, and history of stroke. We also 
additionally adjusted for total cholesterol and lipid-lowering medication use.
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We used linear models to estimate associations between diabetes and cognitive decline, fit 
with generalized estimating equations to account for the within-person correlations of test 
scores arising from the repeated measures across time; unstructured correlation matrices and 
robust variance estimates were employed. Time since baseline was modeled using a linear 
spline with a knot at six years, the mean duration between visits 2 and 4. The spline term 
allows for a non-linear association between time and cognitive decline, more appropriately 
fits the study design than would a quadratic term, and was supported by diagnostic lowess 
smoothers. The primary coefficients of interest were the interactions between diabetes and 
the time spline terms, which address the hypothesis of greater decline among participants 
with diabetes adjusting for age and the other covariates. To examine the role of stroke in 
mediating the association between diabetes and cognitive decline, we censored participant 
values at the time of stroke, excluding any post-stroke cognitive information from our 
analyses. To test the robustness of our findings and to mitigate the differences in baseline 
characteristics between persons with and without diabetes, we reran analyses using 
propensity score matching. Propensity scores were developed using logistic regression and 
included sex, age, race-center, education, cigarette smoking, drinking status, hypertension 
status, prevalent CHD, prevalent stroke, and body mass index. All but 3 participants with 
diabetes were matched (details in Appendix).
We tested for effect modification between race and diabetes, and tested for linear trend 
across categories of HbA1c using a variable taking on values 1 through 5 for each category.
In a separate analysis we examined the association of diabetes duration on 14-year cognitive 
decline, using visit 4 as baseline, and information from all prior visits to categorize diabetes 
duration. We calculated duration as the difference between the date of the visit 4 exam and 
the date of the visit when diabetes was first identified (based on a diagnosis or elevated 
glucose at any prior visit) and categorized as follows: 1) no diabetes at visit 4 (reference), 2) 
diabetes duration <3 years, 3) diabetes duration 3-6 years, 4) diabetes duration 6-9 years, or 
5) diabetes duration >9 years.
We used an inverse probability of attrition weighting (IPAW)(26, 27) approach to account 
for potential informative missingness effects (details in Appendix). Statistical analyses were 
performed with SAS 9.3 (SAS Institute, Cary, NC) and Stata 13.0 (StataCorp LP, College 
Station TX). PROC GENMOD was used for the generalized linear models, with a repeated 
statement to account for correlations between observations, and a weight statement to 
incorporate the IPAW weights.
Results
The mean age of participants at baseline was 57 years, 56% were female, 24% were black, 
and 13.3% had diabetes (Table 1). Participants with diabetes were older, had less education 
and lower cognitive scores, and had a more adverse cardiovascular risk factor profile at 
baseline than those without diabetes. Persons with diabetes at baseline were less likely to 
attend visit 5 (25% versus 48%), which was largely due to the cumulative incidence of 
mortality (46% versus 22%) rather than study dropout (29% versus 30%)(Table 1). Those 
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with the lowest Z scores at visit 2 (<5th percentile) were also less likely to attend visit 5, 
with only 20% returning. Of the 13,351 participants who attended visit 2, 17% did not attend 
any follow-up visits. Of the remaining 83% of participants who had at least one follow-up 
visit (10,720 attended visit 4, 5,987 attended visit 5), the median follow-up was 19.3 years 
(25th,75th percentiles: 6.0, 20.9).
Table 2 shows the estimated 20-year decline from our linear models by diabetes status for 
global cognitive Z score, DWRT, DSST, and WFT. Diagnosed diabetes was associated with 
significantly greater decline in global cognitive Z score, the DSST, and the WFT although 
not in the DWRT. The average decline over 20 years in global cognitive Z score was 0.78 in 
persons without diabetes and 0.92 in persons with diabetes (difference: -0.15, 95% CI: 
(-0.22, -0.08)), i.e. a 19% greater decline among persons with diabetes (-0.15/-0.78=19%). 
The difference was similar in race-stratified analyses (p-for-interaction=0.4357, eTables 
1-4). Adjusting for attrition using IPAW strengthened the magnitude of all associations by 
about 50%. To give these results some context, and because age-related decline in cognitive 
function is well-established, we used our linear model to estimate how much older a person 
without diabetes would need to be at baseline to have, on average, a 0.15 lower Z score. We 
estimated that a participant had to be 4.9 years older. In other words, a 0.15 lower Z score is 
equivalent to the difference in cognitive performance of a 60 year old versus to a 55 year 
old, who are otherwise similar (details in Appendix).
Our results were robust to an alternative analytical approach using propensity score 
matching (eTable5-6, eFigure2). Results were also unchanged when we adjusted for total 
cholesterol, cholesterol-lowering medication use, or when using time-varying covariates. In 
our stroke mediation analysis, excluding post-stroke cognitive scores reduced the 20-year 
difference in cognitive decline between persons with and without diabetes by 13%, though 
results remained significant (eTable7).
Using visit 4 as baseline shows that duration of diabetes was associated with significantly 
greater subsequent 14-year cognitive decline (Table 3). The p-value for linear trend across 
categories was significant for all tests.
Figure 1 shows differences in 20-year decline in global cognitive Z score by clinical 
categories of HbA1c. The p-value for linear trend across all categories was significant 
(p=0.0367 without adjustment for attrition and p=0.006 for the attrition-adjusted values). 
Persons without diagnosed diabetes but HbA1c of 5.7-6.4% at baseline had significantly 
more cognitive decline over 20 years (adjusted difference in global cognitive Z score=-0.07, 
p-value=0.005) compared to persons without diabetes and HbA1c<5.7%. Persons without 
diagnosed diabetes but with HbA1c≥6.5% (undiagnosed diabetes) also had a greater decline 
in cognitive score compared to the reference group, however this difference was not 
statistically significant (p-value=0.105). The greatest decline was found in the group with 
diabetes and HbA1c≥7.0%. Participants in this group had a larger decline compared to 
persons with diabetes and HbA1c<7% (adjusted difference in global cognitive Z 
score=-0.16, p-value=0.071), which was borderline statistically significant. Adjusting for 
attrition strengthened the magnitude of all associations.
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In this community-based population, we found significantly greater cognitive decline among 
both black and white adults with diabetes compared to those without diabetes at baseline, 
with 20-year cognitive decline 19% larger in this group for the global score, or 30% larger 
after accounting for attrition. Duration of diabetes appeared to be a factor, with later life 14-
year decline greater for participants with longer duration of diabetes. There were trends of 
increased cognitive decline across clinical categories of HbA1c, even among persons 
without a history of diabetes. Those with HbA1c in the 5.7-6.4% range (pre-diabetes) hhfda 
and those with HbA1c≥6.5% (undiagnosed diabetes) at baseline had larger declines over 20 
years than those with HbA1c<5.7%. Excluding person with stroke post-baseline attenuated 
the results slightly, suggesting stroke partially mediates the association between diabetes and 
cognitive decline.
The observed association of diabetes with decline in global cognitive function was primarily 
driven by declines in the DSST and WFT, which reflect impairments in the processing speed 
and executive function domains(28, 29). These results suggest that the association of 
diabetes with cognitive function may involve the subcortical microvasculature that damages 
white matter pathways or subcortical grey matter in other ways(30-32). However, we also 
found associations with memory, but only in whites, after adjustment for attrition. This may 
be due to the fact that the DWRT, with only 10 words, is insensitive to small declines in 
memory.
Previous studies of diabetes and cognitive decline have mostly been short in duration: 
Cukierman's review included only one study with mean follow-up of more than 6 years' 
duration(6). In four recent reports, diabetes was associated with 12-year decline in several 
tests in the Maastricht Study(33), 10-year decline in a global test, memory, and reasoning in 
two Whitehall II studies(15, 34), and 8-year decline in one of 8 tests in the Framingham 
Offspring Study(35). However, only one of these reported associations with diabetes 
diagnosed before age 65.
ACCORD-MIND, a randomized clinical trial, showed that tight glucose control in elderly 
diabetics with high cardiovascular risk did not reduce cognitive decline measured by 
DSST(13, 14). Some have postulated that the lack of benefit in ACCORD-MIND may have 
been due to the older age of participants (mean age 63), the short treatment period (3.3 
years), and a higher frequency of hypoglycemic episodes in the treatment compared to the 
control arm. However, our observations that higher HbA1c levels were associated with 
greater 20-year cognitive decline even in persons without a diagnosis of diabetes, and that 
longer duration of diabetes was associated with greater cognitive decline, suggests that a 
long-term trial, if one were feasible, could demonstrate the cognitive benefit of glycemic 
control. The potential benefit of early intervention deserves further study(36).
Some limitations of our study deserve consideration. We had only one test in each cognitive 
domain at each visit and only a single measurement of HbA1c at baseline. Blacks in ARIC 
come from just 2 study sites, limiting our ability to fully separate the effects of race from 
those of geography. Attrition is a likely concern for any long-term study. However, our 
Rawlings et al. Page 7













attrition-adjustment likely provides less biased estimates of the effect of diabetes on 
cognition than when attrition is ignored, as in most prior reports. Although we adjusted for 
attrition using a broad set of available data, it is possible that our method of adjustment does 
not fully account for the effects of drop out, especially dropout directly related to low 
cognitive function, and our estimate of the association of diabetes with cognitive decline 
may remain conservative. As this is an observational study, we cannot conclude that the link 
between diabetes and cognitive decline is causal, and we cannot rule out the possibility of 
residual confounding.
Strengths of this study include the large community-based population of blacks and whites, 
rigorous assessment of variables that might affect the association between diabetes and 
cognitive function, and our methods to reduce the effects of dropout. The evaluation of 
cognitive change over time, with 20-year duration of follow-up with cognitive function 
assessed at several time points, is also a particular strength of this study. Rather than 
assessing dementia or cognitive performance at a single time point, examining scores over 
time reduces the influence of confounding variables(20).
Maintaining cognitive function is a critical aspect of successful aging and for ensuring a 
high quality of life. Diabetes and glucose control are potentially modifiable and may offer an 
important opportunity for the prevention of cognitive decline, thus delaying progression to 
dementia. At the population level, delaying the onset of dementia by even a couple of years 
could reduce the prevalence of dementia by more than 20% over the next 30 years(37).
This study documents that diabetes and pre-diabetes in middle age are associated with 
greater cognitive decline over the subsequent two decades. The association with cognitive 
decline was stronger for diabetes of longer duration, and our findings were similar in black 
and white adults. These data suggest that primary prevention of diabetes or glucose control 
in midlife may protect against later-life cognitive decline.
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Difference in global cognitive Z score decline by clinical categories of hemoglobin A1c 
compared to decline in persons without diabetes with hemoglobin A1c < 5.7%.
Legend: Adjusted for attrition refers to the inverse probability of attrition weighting used to 
account for participant death or dropout during follow-up. Estimates (95% confidence 
intervals) are from generalized linear models fit using generalized estimating equations for 
global cognitive Z score, with adjustment for age, age-squared, race-center, sex, education, 
cigarette smoking status, drinking status, hypertension, history of coronary heart disease, 
history of stroke, APOE ε4 genotype, body mass index, interactions between these variables 
and time (except for drinking status and history of coronary heart disease, which were not 
significant), and interactions between race-center and sex, hypertension, and education. 
Hemoglobin A1c was categorized using the standard clinical cut-points based on American 
Diabetes Association criteria (in participants without a diagnosis of diabetes (N=12,107): 
<5.7% (N=9,031), 5.7-6.4% (N=2,365), and ≥6.5% (N=711); in participants with diagnosed 
diabetes(N=1,244): <7% (N=415), ≥7% (N=829).
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Table 1







Age 57.0 (5.7) 58.2 (5.7) 56.8 (5.7)
Female, % 55.6 57.2 55.3
Visit 5 Attendance, %
 Died before visit 5 25.4 46.4 22.1
 Alive, but did not attend 29.8 28.6 30.0
 Attended 44.8 25.1 47.9
Race-Center, %
 Minneapolis - White 26.9 13.9 28.8
 Washington County - White 26.2 24.6 26.4
 Forsyth - White 23.3 16.5 24.4
 Forsyth - Black 2.7 4.9 2.4
 Jackson - Black 21.0 40.1 18.0
Cognitive scores
 Global cognitive Z score 0.00 (1.0) -0.52 (1.0) 0.08 (1.0)
 Delayed word recall test, number of words Recalled 6.6 (1.5) 6.1 (1.6) 6.7 (1.5)
 Digit symbol substitution test, number of symbols translated 44.7 (14.2) 36.9 (14.4) 45.9 (13.7)
 Word fluency test, number of words generated 33.2 (12.5) 29.3 (12.4) 33.8 (12.4)
Hemoglobin A1c 5.8 (1.2) 8.0 (2.1) 5.4 (0.4)
Prevalent coronary heart disease, % 5.7 11.1 4.8
Prevalent stroke, % 1.7 4.4 1.3
Apolipoprotein E ε4 alleles, %
 0 69.2 69.4 69.2
 1 28.1 27.8 28.2
 2 2.6 2.9 2.6
Hypertension, % 35.6 59.0 32.0
Body mass index, kg/m2 28.0 (5.4) 31.4 (6.1) 27.4 (5.1)
Total cholesterol level
 mg/dL 210 (39.5) 216 (45.5) 209 (38.4)
 mmol/L 5.43 (1.02) 5.57 (1.18) 5.41 (0.99)
HDL cholesterol level
 mg/dL 49.4 (16.7) 43.1 (14.2) 50.4 (16.8)
 mmol/L 1.28 (0.43) 1.11 (0.37) 1.30 (0.44)
Triglyceride level
 mg/dL 136 (90.3) 178 (135.3) 130 (79.4)
 mmol/L 1.54 (1.02) 2.01 (1.53) 1.46 (0.90)
Education, %
 Less than high school 21.2 34.9 19.1
 High school, graduate equivalence degree, or vocational school 41.8 37.9 42.3
 College, graduate, or professional school 37.0 27.2 38.6




















Cigarette smoking status, %
 Current 22.3 20.8 22.5
 Former 37.9 37.0 38.1
 Never 39.8 42.2 39.4
Alcohol consumption, %
 Current 56.6 36.0 59.7
 Former 20.8 33.2 18.9
 Never 22.6 30.8 21.3
Age, cognitive scores, hemoglobin A1c, body mass index, total cholesterol, HDL cholesterol, and triglycerides are means (SD). All other values are 
percentages.













Rawlings et al. Page 15
Table 2
Average difference in 20-year decline in global cognitive Z score, delayed word recall, digit symbol 




20 year decline – No diabetes
Estimate (95% CI)
20 year decline – Diabetes
Estimate (95% CI)
Difference*
Estimate (95% CI) Percent†
Global Z -0.78 (-0.80, -0.75) -0.92 (-1.00, -0.85) -0.15 (-0.22, -0.08) 19%
Delayed Word Recall Test -0.98 (-1.02, -0.94) -1.04 (-1.15, -0.92) -0.06 (-0.17, 0.06) 6%
Digit Symbol Substitution Test -0.69 (-0.71, -0.67) -0.82 (-0.87, -0.77) -0.13 (-0.18, -0.08) 19%
Word Fluency Test -0.17 (-0.19, -0.14) -0.28 (-0.35, -0.22) -0.12 (-0.18, -0.06) 71%
Attrition-adjusted
Test 20 year decline – No diabetes 20 year decline – Diabetes Difference* Percent†
Global Z -0.79 (-0.82, -0.76) -1.01 (-1.11, -0.92) -0.23 (-0.32, -0.13) 29%
Delayed Word Recall Test -1.01 (-1.05, -0.96) -1.09 (-1.22, -0.96) -0.09 (-0.22, 0.04) 9%
Digit Symbol Substitution Test -0.70 (-0.72, -0.68) -0.87 (-0.94, -0.81) -0.18 (-0.24, -0.11) 26%
Word Fluency Test -0.17 (-0.20, -0.14) -0.37 (-0.47, -0.28) -0.21 (-0.31, -0.10) 124%
*
Calculated as the difference in 20-year decline between persons without and with diabetes (negative values indicate greater decline in persons 
with diabetes)
†
Calculated as the difference expressed as a percentage of the decline in those without diabetes. That is, (decline in participants without diabetes – 
decline in participants with diabetes)/(decline in participants without diabetes); thus a value of 19% indicates a 19% greater decline in those with 
diagnosed diabetes compared to those without. Note that the differences and percent declines are calculated before rounding of 20-year estimates.
Note: bold values indicate p-value < 0.05. Z scores can be interpreted as standard deviations above or below the mean. For example, a Z score 
difference of -0.15 means that, on average, persons with diabetes declined an additional 0.15 standard deviations compared to persons without 
diabetes. Time since baseline was the time metric, and cognitive function was modeled using generalized linear models fit using generalized 
estimating equations, with adjustment for age, age squared, race-center, sex, education, cigarette smoking, alcohol consumption, body mass index, 
hypertension, history of coronary heart disease, history of stroke, APOE ε4 genotype, and interactions between all of these covariates and time. 
N=30,058 total records, with N=13,351 participants at visit 2(N=1,779 with diabetes), N=10,720 at visit 4(N=1,209 with diabetes), and N=5,987 at 
visit 5(N=446 with diabetes).
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